President John Mahama has appointed Prof. Kwabena Frimpong-Manso Opuni as the Acting Chief Executive Officer of the Food and Drugs Authority (FDA), following the departure of long-serving regulator Delese Mimi Darko.
The change in leadership takes effect on Monday (14 July), Asaase News has gathered.
It comes at a time when the FDA is under renewed focus for ensuring quality control of pharmaceuticals, food products, and vaccines.
Profile
Prof. Manso-Opuni brings with him nearly two decades of regulatory, academic, and pharmaceutical experience. A registered pharmacist since 2003 and a certified Project Management Professional, he joined the FDA in 2006 and later transitioned to academia, where he currently serves as an Associate Professor in Pharmaceutical Chemistry at the University of Ghana’s School of Pharmacy.
He holds a PhD in Pharmaceutical Chemistry from the University of Rostock, Germany, and is a recipient of several international fellowships and grants, including a postdoctoral fellowship and the Hermes grant which allowed him to study at the University of Washington, USA.
Prof. Manso-Opuni is widely respected in pharmaceutical and regulatory circles, having served as a consultant for major global institutions such as the United States Pharmacopoeia Convention, the West Africa Health Organization, and PricewaterhouseCoopers Ghana. He has also played key roles in regulatory training across Liberia, Eritrea, and Ghana, particularly during the COVID-19 pandemic.
He is a member of multiple international scientific bodies, including the Royal Society of Chemistry, American Society for Mass Spectrometry, and the Pharmaceutical Society of Ghana.
Known as an advocate for access to safe, effective, and affordable medicines, his appointment is being seen as a move to deepen regulatory science and reinforce the FDA’s credibility.
Source: Asaaseradio.com
Discussion about this post